In episode #9 of the ChalkTalk podcast, we speak with Alexandra Lansky, MD, FACC, FAHA, FSCAI, FESC, Professor of Medicine in Cardiology, and Director of Yale Cardiovascular Clinical Research Program at Yale University School of Medicine in New Haven, Connecticut, about her recent gender analyses at TCT21 and SCAI22, in which she presented the respective 30-day and 1-year outcomes broken out by women vs men that were enrolled in the Disrupt CAD clinical program.
Dr. Lansky shares the genesis of the analysis - previous research showing that female atherectomy patients have an increased risk for angiographic complications than their male counterparts,[i] and sheds light on what makes coronary IVL unique from a safety perspective. She concludes by discussing the recent publication of SCAI’s “Expert Consensus Statement on Sex-Specific Consideration in Myocardial Revascularization” in JSCAI, which referenced the role of IVL in female patients. The SCAI guidelines concluded, “while additional evidence is needed, these results taken in the context of outcomes with atherectomy devices suggest that IVL may emerge as a first-line therapy for plaque modification of calcified lesions in women specifically.”
We hope you enjoy the episode and for more information on coronary IVL in women, please visit TimeForAnIntervention.com.
Read More
Topics:
Shockwave Behind-the-Scenes,
Coronary IVL,
Shockwave Breaking News,
IVL Technology,
Coronary Cases,
Coronary Clinical Data,
Shockwave C2,
Coronary Conferences,
Coronary IVL - U.S.,
ChalkTalk Podcast
In a few weeks, we are headed to a city known for its sunshine and southern hospitality, Atlanta, Georgia, where SCAI 2022 is taking place this year. At the conference, leading calcium experts will share the 1-year results from the Randomized Disrupt PAD III Trial and 1-year sex specific outcomes with Coronary IVL.
Read More
Topics:
Coronary IVL,
IVL Case,
Peripheral IVL,
Shockwave Breaking News,
IVL Technology,
DISRUPT PAD,
Coronary Cases,
Peripheral Cases,
PAD Applications - BTK,
Peripheral Conferences,
SWAV News,
Shockwave C2,
Coronary Conferences,
Shockwave M5,
Shockwave S4,
PAD Applications - TEVAR,
Coronary IVL - U.S.,
ShockwaveM5+
After two long years, EuroPCR is finally live again! We can’t wait to meet you in Paris and discuss the latest on IVL.
Read More
Topics:
Coronary IVL,
IVL Case,
IVL Technology,
Coronary Cases,
Shockwave C2,
Coronary IVL - U.S.
Some of us know the data. Some don’t. The question once you do is where we go from here to bridge the gender inequality gap?
Read More
Topics:
Coronary IVL,
IVL Case,
IVL Technology,
Coronary Cases,
Shockwave C2,
Coronary IVL - U.S.
Discover our PCR webinar featuring European calcium experts, Prof Emanuele Barbato, Prof Javier Escaned, Dr Margaret McEntegart, and Prof Flavio Luciano Ribichini discussing about the most recent OCT data analysis from Disrupt CAD Trials.
Read More
Topics:
Coronary IVL,
IVL Case,
IVL Technology,
Coronary Cases,
Shockwave C2,
Coronary IVL - U.S.
Prof. Javier Escaned, Hospital Universitario Clínico San Carlos, Madrid, and Prof. James Spratt, St George’s University Hospital NHS Trust, London, discussed with Cardiovascular News their views about the latest data from the pooled analysis of 262 patients enrolled in OCT sub-studies from Disrupt CAD I, II, III, & IV.
Read More
Topics:
Coronary IVL,
IVL Case,
IVL Technology,
Coronary Cases,
Shockwave C2,
Coronary IVL - U.S.
Dr. Benjamin Honton, Interventional Cardiologist at Clinique Pasteur, Toulouse, France, together with Dr. Jacques Monsegu, Groupe Hospitalier Mutualiste de Grenoble, France, write about best practices for IVL use in the cath lab based on his 3 years of experience with the technology. In this review you will find IVL technical, scientific and clinical overview, such as lesion selection with focus on concentric and eccentric calcification, analysis of specific clinical indications and some useful tips for crossing and therapy delivery.
Read More
Topics:
Coronary IVL,
IVL Case,
IVL Technology,
Coronary Cases,
Shockwave C2,
Coronary IVL - U.S.
Based on Shockwave’s recognition on Fast Company’s 2022 list of the World’s Most Innovative Companies in the medical device sector for “bringing good vibrations to heart procedures,” we sat down with Shockwave CEO Doug Godshall for a Q&A to discuss how innovation is fostered at SWAV and why continual innovation is imperative to the future success of the company.
You can also read more about the honor in the company’s press release, in which Doug is quoted saying, “Shockwave Medical was founded with innovation at our core…not only for pioneering revolutionary and proprietary IVL technology, but also for the ways that innovation permeates every aspect of our business. We are continually evolving and transforming how we do things as we seek to astound our customers with life changing products for the treatment of calcified cardiovascular disease.”
Read More
Topics:
Shockwave Behind-the-Scenes,
Coronary IVL,
Peripheral IVL,
IVL Technology,
ChalkTalk Podcast
Disrupt CAD Pooled Gender Analysis is now in published in JSCAI - the new journal of the Society for Cardiovascular Angiography & Interventions. Read the JSCAI publication here: https://www.jscai.org/article/S2772-9303(21)00011-9/fulltext
Read More
Topics:
Coronary IVL,
IVL Case,
IVL Technology,
Coronary Cases,
Shockwave C2,
Coronary IVL - U.S.
The one-year Disrupt CAD III data has been published in JSCAI – the new journal of the Society for Cardiovascular Angiography & Interventions. The new data from Disrupt CAD III confirm the consistency of the excellent safety and effectiveness outcomes at 30 days out to one year.
Read More
Topics:
Coronary IVL,
IVL Case,
IVL Technology,
Coronary Cases,
Shockwave C2,
Coronary IVL - U.S.
